PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Could a cancer drug hold the key to a HIV cure?

Could a cancer drug hold the key to a HIV cure?
2023-08-30
(Press-News.org)

An existing blood cancer drug has shown promise in killing ‘silent’ HIV cells and delaying reinfections – a significant pre-clinical discovery that could lead to a future cure for the disease.

Hidden HIV cells, known as latent infection, are responsible for the virus permanently remaining in the body and cannot be treated by current therapy options. These hibernating, infected cells are the reason why people living with HIV require life-long treatment to suppress the virus.


Led by WEHI and The Peter Doherty Institute for Infection and Immunity (Doherty Institute) -- leading medical research institutes in Melbourne, Australia -- the landmark study is being translated into a new clinical trial to assess whether the blood cancer treatment can be repurposed to offer a pathway towards an HIV cure. 


Watch and embed the video: https://youtu.be/o7fjKzW4cvM


At a glance

A joint WEHI and Doherty Institute study finds the cancer drug venetoclax – based on a groundbreaking research discovery at WEHI – can kill hibernating HIV-infected cells and, crucially, delay the virus from re-emerging. While current treatments can suppress the virus, they cannot target hibernating HIV-infected cells and permanently prevent the virus from coming back. A clinical trial based on the findings will launch in Denmark and Australia, to test whether venetoclax can be used as a potential pathway to develop a cure for HIV.

 


An estimated 39 million people worldwide are living with HIV, including more than 29,400 Australians.

Antiretroviral therapy (ART) is the standard of care treatment given to people living with HIV and is highly effective. But the medication cannot target hibernating HIV-infected cells, meaning it can only suppress the virus – not cure it.  

ART for people living with HIV is life-long: if a person stops taking this medication, hibernating HIV-infected cells will reactivate within a very short timeframe, leading to a resurgence of the virus. 

An estimated 98% of Australians living with HIV currently have undetectable levels of the virus, as it is completely suppressed by their ongoing ART treatment.

In the new study, WEHI researchers used the cancer drug venetoclax on enhanced pre-clinical models of HIV and found it delayed the virus from rebounding by two weeks, even without ART.

Co-first author, Dr Philip Arandjelovic from WEHI, said the discovery is an exciting step towards developing treatment options for the tens of millions of people currently living with HIV globally.

“In attacking dormant HIV cells and delaying viral rebound, venetoclax has shown promise beyond that of currently approved treatments,” he said.
“Every achievement in delaying this virus from returning brings us closer to preventing the disease from re-emerging in people living with HIV. Our findings are hopefully a step towards this goal.”

The study marks the first time venetoclax has been used on its own to assess HIV persistence in pre-clinical models. 

However, researchers also found the cancer treatment can be combined with another drug that acts on the same pathway and is currently in clinical trials, to achieve a longer delay in viral rebound, with a shorter duration of venetoclax treatment.

“It has long been understood that one drug may not be enough to completely eliminate HIV. This finding has supported that theory, while uncovering venetoclax’s powerful potential as a weapon against HIV,” Dr Arandjelovic said.


Lifelong memory game

HIV primarily targets CD4+ T cells, a type of white blood cell crucial for the immune system to properly function. 

It is within these cells that HIV can lie dormant, ready to reactivate if the virus is not effectively eliminated.

Using human CD4+ T cells donated by people living with HIV who are on suppressive ART, scientists at the Doherty Institute found venetoclax was also able to reduce the amount of HIV DNA in these white blood cells.

Co-first author, The University of Melbourne’s Dr Youry Kim and a Postdoctoral researcher at the Doherty Institute, said venetoclax potently reduced the amount of intact viral DNA in patient cells when studied in the laboratory. 

“This indicates that venetoclax is selectively killing the infected cells, which rely on key proteins to survive. Venetoclax has the ability to antagonise one of the key survival proteins,” said Dr Kim.

Milestone trial

Venetoclax, marketed as VENCLEXTA, is based on a landmark discovery by Professor David Vaux AO in 1988. The drug is the result of a research collaboration between WEHI and companies Roche, Genentech (a member of the Roche Group) and AbbVie. It was developed by Roche, Genentech and AbbVie and co-developed and trialled in Australia.

The Phase I/IIb clinical trial using venetoclax to treat HIV will start at the end of the year in Denmark, with plans to expand the study to Melbourne in 2024. It will be led by Professor Sharon Lewin (Director of the Doherty Institute), Professor Marc Pellegrini (Executive Director at the Centenary Institute) and Dr Thomas Rasmussen (clinician scientist at Denmark’s Aarhus University).

Prof Marc Pellegrini, a joint corresponding author and WEHI Honorary Fellow, said the trial will replicate the pre-clinical study conducted using WEHI’s state-of-the-art technology and facilities.

“The trial will assess the safety and tolerability of venetoclax in people living with HIV who are on suppressive antiretroviral therapy,” said Prof Pellegrini, a former Head of WEHI’s Infectious Diseases and Immune Defence Division.

Melbourne Laureate Professor Sharon Lewin, a joint corresponding author, concluded:  “It’s exciting to see venetoclax, which has already helped thousands of blood cancer patients, now being repurposed as a treatment that could also help change the lives of people living with HIV and put an end to the requirement for life-long medication.”

The research was supported by the National Health and Medical Research Council (NHMRC), The Sylvia & Charles Viertel Senior Medical Research Fellowship, Australian Centre for HIV and Hepatitis Virology Research, the Victorian Government and Australian Government.

The study, “Venetoclax, alone and in combination with the BH3-mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice”, involves collaborations with the University of Melbourne and Royal Melbourne Hospital, and is published in Cell Reports Medicine.

END


[Attachments] See images for this press release:
Could a cancer drug hold the key to a HIV cure? Could a cancer drug hold the key to a HIV cure? 2

ELSE PRESS RELEASES FROM THIS DATE:

Robustness of the world's skyscrapers stress-tested by Surrey model

2023-08-30
The safety of tall buildings in the world's cities, in the face of extreme external traumas like vehicle impacts, blasts or fires, has been tested using a model developed by structural engineers at the University of Surrey – with reassuring results.  Surrey's structural engineers partnered with industry experts to check and enhance the robustness of skyscrapers. Surrey's researchers collaborated with experts at the respected collective of architects, designers, engineers and planners, Skidmore, Owings & Merrill (SOM), famous for buildings like the Burj Khalifa, the world's tallest skyscraper, and the Sears ...

Inequities in cardiovascular care are putting older female’s heart health at risk

Inequities in cardiovascular care are putting older female’s heart health at risk
2023-08-30
Toronto, ON, August 30, 2023 – Higher stroke risk among females with atrial fibrillation may be related to sex-based disparities in cardiovascular care, according to a new study from Women’s College Hospital, the Peter Munk Cardiac Centre (PMCC) at University Health Network (UHN) and ICES. Atrial fibrillation (AF) is a common type of irregular heart rhythm that is associated with a higher risk of stroke—after the age of 40, one in four strokes are caused by AF. Previous studies have found that female sex (assigned at birth) is a risk factor for AF-associated stroke. Recent research suggested that ...

Surprising study results: Students are bored during exams

2023-08-30
In the case of boredom, we think of many situations in life but intuitively not of exams. However, an international team of academics led by Thomas Götz from the University of Vienna has now studied exactly this phenomenon of test boredom for the first time and found remarkable results. According to the study, school students are actually very bored during exams. The study also showed that utter boredom has a negative effect on exam results. The research results have been published recently in the Journal of Educational Psychology.  Although boredom is currently a very intensively studied phenomenon, test boredom has so far been completely ignored ...

Study reveals important associations between gut microbiome and eczema in infancy

2023-08-30
Washington, D.C. –  A new study has revealed important associations between the gut microbiome and eczema in infancy and has established the basis for the potential prevention and treatment of eczema via modulation of the gut microbiota. The study was published in mSystems, a journal of the American Society for Microbiology. “The problem of eczema is increasing, and our study shows it could be a result of unwanted changes in the gut bacterial content. The first year of life could be a critical period to restore the gut bacteria to a more desirable composition,” said the study’s principal investigator ...

Adapting Ritalin® to tackle cocaine abuse

2023-08-30
Cocaine use continues to be a public health problem, yet despite concerted efforts, no drugs have been approved to resolve cocaine addiction. Research suggests that the attention-deficit/hyperactivity disorder drug methylphenidate (MPH; Ritalin®) could serve as a cocaine-replacement therapy, but clinical results have been mixed. Although several labs have produced MPH derivatives for testing, parts of the molecule remained chemically inaccessible. Now, researchers reporting in ACS Central Science have cleared that hurdle. According to the Centers for Disease Control and Prevention, more than 5 million Americans ...

A new way to capture and recycle carbon dioxide from industrial emissions

2023-08-30
Carbon capture is a promising method to help slow climate change. With this approach, carbon dioxide (CO­­2) is trapped before it escapes into the atmosphere, but the process requires a large amount of energy and equipment. Now, researchers reporting in ACS Central Science have designed a capture system using an electrochemical cell that can easily grab and release CO2. The device operates at room temperature and requires less energy than conventional, amine-based carbon-capture systems. Many industries are turning ...

Nuclear weapons tests are unappreciated source of radioactivity in German wild boars

2023-08-30
Shaggy-haired, tusked pigs roam free in the woods of Germany and Austria. Although these game animals look fine, some contain radioactive cesium at levels that render their meat unsafe to eat. Previously, scientists hypothesized that the contamination stemmed from the 1986 Chernobyl nuclear power plant accident. But now, researchers in ACS’ Environmental Science & Technology report that nuclear weapon fallout from 60 to 80 years ago also contributes significantly to the wild boars’ persistent radioactivity. Radioactive cesium, a byproduct of nuclear weapons explosions and nuclear ...

ESO telescopes help unravel pulsar puzzle

ESO telescopes help unravel pulsar puzzle
2023-08-30
With a remarkable observational campaign that involved 12 telescopes both on the ground and in space, including three European Southern Observatory (ESO) facilities, astronomers have uncovered the strange behaviour of a pulsar, a super-fast-spinning dead star. This mysterious object is known to switch between two brightness modes almost constantly, something that until now has been an enigma. But astronomers have now found that sudden ejections of matter from the pulsar over very short periods are responsible for the peculiar switches. “We have witnessed extraordinary cosmic events where enormous amounts of matter, similar to cosmic cannonballs, are launched into ...

Novel chemosensor-based method for rapid detection of bacterial toxin

Novel chemosensor-based method for rapid detection of bacterial toxin
2023-08-30
The COVID-19 pandemic made it very clear that we need better methods to quickly screen for dangerous pathogens and substances. One such compound that regularly flies under the radar is lipopolysaccharide (LPS), largely known as "endotoxins." This molecule, which is found in the outer membrane of Gram-negative bacteria, can be very harmful to humans. It can trigger a major immune response, producing fever and inflammation. In the worst cases, it can cause organ failure due to sepsis. Surprisingly, for such a ubiquitously present toxin, there are very few ways to effectively detect the presence of LPS. The gold standard for its detection is the limulus amebocyte ...

How a mere 12% of Americans eat half the nation’s beef, creating significant health and environmental impacts

2023-08-30
A new study has found that 12% of Americans are responsible for eating half of all beef consumed on a given day, a finding that may help consumer groups and government agencies craft educational messaging around the negative health and environmental impacts of beef consumption. Those 12% – most likely to be men or people between the ages of 50 and 65 – eat what researchers called a disproportionate amount of beef on a given day, a distinction based on the latest Dietary Guidelines for Americans, which suggest 4 ounces per day of meat, poultry, and eggs combined for those consuming 2200 ...

LAST 30 PRESS RELEASES:

Exercise as an anti-ageing intervention to avoid detrimental impact of mental fatigue

UMass Amherst Nursing Professor Emerita honored as ‘Living Legend’

New guidelines aim to improve cystic fibrosis screening

Picky eaters by day, buffet by night: Butterfly, moth diets sync to plant aromas

Pennington Biomedical’s Dr. Leanne Redman honored with the E. V. McCollum Award from the American Society for Nutrition

CCNY physicists uncover electronic interactions mediated via spin waves

Researchers’ 3D-printing formula may transform future of foam

Nurture more important than nature for robotic hand

Drug-delivering aptamers target leukemia stem cells for one-two knockout punch

New study finds that over 95% of sponsored influencer posts on Twitter were not disclosed

New sea grant report helps great lakes fish farmers navigate aquaculture regulations

Strain “trick” improves perovskite solar cells’ efficiency

How GPS helps older drivers stay on the roads

Estrogen and progesterone stimulate the body to make opioids

Dancing with the cells – how acoustically levitating a diamond led to a breakthrough in biotech automation

Machine learning helps construct an evolutionary timeline of bacteria

Cellular regulator of mRNA vaccine revealed... offering new therapeutic options

Animal behavioral diversity at risk in the face of declining biodiversity

Finding their way: GPS ignites independence in older adult drivers

Antibiotic resistance among key bacterial species plateaus over time

‘Some insects are declining but what’s happening to the other 99%?’

Powerful new software platform could reshape biomedical research by making data analysis more accessible

Revealing capillaries and cells in living organs with ultrasound

American College of Physicians awards $260,000 in grants to address equity challenges in obesity care

Researchers from MARE ULisboa discover that the European catfish, an invasive species in Portugal, has a prolonged breeding season, enhancing its invasive potential

Rakesh K. Jain, PhD, FAACR, honored with the 2025 AACR Award for Lifetime Achievement in Cancer Research

Solar cells made of moon dust could power future space exploration

Deporting immigrants may further shrink the health care workforce

Border region emergency medical services in migrant emergency care

Resident physician intentions regarding unionization

[Press-News.org] Could a cancer drug hold the key to a HIV cure?